The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27816515 |
143 |
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors. |
Merck |
27311891 |
14 |
Enriching screening libraries with bioactive fragment space. |
Beijing University of Technology |
26985319 |
36 |
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo. |
Astrazeneca |
26465079 |
6 |
Computational Tools To Model Halogen Bonds in Medicinal Chemistry. |
Colorado State University |
26850376 |
36 |
Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors. |
Kyoto University |
26778657 |
10 |
Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity. |
Warsaw University of Technology |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
25007344 |
73 |
Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorß (PDGF-Rß) guided by water thermodynamics. |
Christian-Albrechts-University of Kiel |
25036794 |
12 |
Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2a and cytotoxicity properties. |
Warsaw University of Technology |
24681986 |
42 |
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. |
Siedlce University of Natural Sciences and Humanities |
24359159 |
60 |
Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. |
Astrazeneca |
24100158 |
148 |
Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). |
Nerviano Medical Sciences |
24900749 |
6 |
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. |
Astrazeneca |
23249297 |
75 |
Trimeric hemibastadin congener from the marine sponge Ianthella basta. |
Heinrich-Heine University |
22339433 |
48 |
Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. |
Kyoto University |
22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. |
Cellzome |
22924342 |
15 |
Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. |
Cylene Pharmaceuticals |
24900464 |
66 |
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization. |
TBA |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
8824261 |
8 |
Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. |
Institute For Biochemistry |
17360485 |
10 |
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. |
Millennium Pharmaceuticals |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
17983756 |
55 |
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. |
Osi Pharmaceuticals |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. |
Abbott Laboratories |
22115617 |
64 |
CK2a and CK2a' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. |
The John Paul Ii Catholic University of Lublin |
22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). |
Ansaris |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
21174434 |
13 |
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. |
Cylene Pharmaceuticals |
20965724 |
57 |
Identification of potent ITK inhibitors through focused compound library design including structural information. |
Nycomed |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
20472330 |
16 |
Novel 8-arylated purines as inhibitors of glycogen synthase kinase. |
Institut Curie |
19414254 |
6 |
Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. |
Osaka Prefecture University |
19168362 |
11 |
Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2. |
Institute of Biochemistry and Biophysics |
18529047 |
156 |
Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. |
Eberhard-Karls University |
17166835 |
12 |
Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. |
Istituto Di Ricerche Di Biologia Molecolare &Quot;P. Angeletti |
17540560 |
39 |
Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2. |
Polaris Pharmaceuticals |
15261294 |
17 |
Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. |
Michigan State University |
32433887 |
62 |
Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity |
University of Nottingham |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors. |
Merck |
27491711 |
422 |
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties. |
Merck And |
30755337 |
95 |
Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. |
Japan Tobacco |
30689953 |
36 |
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. |
Saarland University |
30689946 |
122 |
2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. |
Universit£ |
31693351 |
473 |
Discovery of 4 |
TBA |
30763817 |
39 |
Identification of an indol-based multi-target kinase inhibitor through phenotype screening and target fishing using inverse virtual screening approach. |
University of Naples Federico Ii |
31400711 |
29 |
Small molecule modulators targeting protein kinase CK1 and CK2. |
China Pharmaceutical University |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. |
University of Florida |
26568289 |
32 |
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
Dana-Farber Cancer Institute |
19271717 |
96 |
Bioactive metabolites from the endophytic fungus Stemphylium globuliferum isolated from Mentha pulegium. |
Heinrich-Heine-Universitat |
18494522 |
244 |
Cytotoxic metabolites from the fungal endophyte Alternaria sp. and their subsequent detection in its host plant Polygonum senegalense. |
Heinrich-Heine-Universit£T |
29288942 |
16 |
A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors. |
Instituto Universitario De Bio-Org£Nica Antonio Gonz£Lez (Cibican) |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups. |
Vertex Pharmaceuticals |
29934219 |
8 |
Identification by Inverse Virtual Screening of magnolol-based scaffold as new tankyrase-2 inhibitors. |
University of Salerno |
29759799 |
74 |
Novel non-ATP competitive small molecules targeting the CK2 ?/? interface. |
University of Cambridge |
29559278 |
99 |
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. |
Astrazeneca |
30217463 |
7 |
Thiazole- and selenazole-comprising high-affinity inhibitors possess bright microsecond-scale photoluminescence in complex with protein kinase CK2. |
University of Tartu |
28274673 |
33 |
Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2. |
University of Tartu |
29087197 |
1 |
Fragment-to-Lead Medicinal Chemistry Publications in 2016. |
Astex Pharmaceuticals |
28495381 |
14 |
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066. |
University of Cambridge |
23578312 |
22 |
Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors. |
Nas of Ukraine |
22299586 |
14 |
Inhibitory effect of novel pyrazole carboxamide derivatives on human carbonic anhydrase enzyme. |
Dumlupinar University |
27346364 |
28 |
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently. |
Korea Institute of Science and Technology |
| 55 |
LPXC in CSAR_FULL_RELEASE_3JULY2012 |
Csar |
19159286 |
14 |
Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR). |
Exelixis |
17585751 |
48 |
Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. |
Amgen |